Blum JL et al. Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. Proc ASCO 2004;Abstract 543.

Fehm T et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res 2004;24(6):4205-10. Abstract

Fujimoto-Ouchi K et al. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5’-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49(3):211-6. Abstract

Gancberg D et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13(7):1036-43. Abstract

Montemurro F et al. Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 2004;5(1):81-96. Abstract

O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in longterm disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract

Sekido Y et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003;22(6):1225-32. Abstract

Xu L et al. Results of a Phase II trial of trastuzumab (Herceptin) plus capecitabine (Xeloda) in patients with previously untreated HER2-positive metastatic breast cancer (MBC). Poster 3049. San Antonio Breast Cancer Symposium 2005.